Correction: Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the “all-around warrior” in immunotherapy

Correction: Mol Cancer 23, 183 (2024)

https://doi.org/10.1186/s12943-024-02095-8

Following publication of the original article [1], the author reported that the published PDF version is incorrect as the information such as “(See Fig. 5)”, “(Fig. 4; Table 3)”, and “[170]” need to be removed and updated accordingly as shown below. The original article has been corrected.

The sentences currently read:

Understanding these regulatory mechanisms and identifying new targets for modifying PD-1/PD-L1 are crucial for advancing precise immunotherapies for genitourinary malignancies (See Fig. 5).

Therefore, understanding the regulatory mechanisms of PD-1/PD-L1 expression is essential for optimizing cancer immunotherapy in these malignancies (Fig. 4; Table 3).

Mutational loads across different tumor types correlate with tumor immunogenicity.Reproduced with permission [170].

The sentences should read:

Understanding these regulatory mechanisms and identifying new targets for modifying PD-1/PD-L1 are crucial for advancing precise immunotherapies for genitourinary malignancies.

Therefore, understanding the regulatory mechanisms of PD-1/PD-L1 expression is essential for optimizing cancer immunotherapy in these malignancies (Fig. 5; Table 3).

Mutational loads across different tumor types correlate with tumor immunogenicity. Reproduced with permission [171].

1. Liu Q, Guan Y, Li S. Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the all-around warrior in immunotherapy. Mol Cancer. 2024;23:183. https://doi.org/10.1186/s12943-024-02095-8.

   Article PubMed PubMed Central Google Scholar

Download references

Authors and Affiliations

1. Department of Urology, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, 110042, Liaoning, China

   Qiang Liu

2. Second Ward of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, 110042, Liaoning, China

   Yujing Guan & Shenglong Li

3. The Liaoning Provincial Key Laboratory of Interdisciplinary Research on Gastrointestinal Tumor Combining Medicine with Engineering, Shenyang, 110042, Liaoning, China

   Yujing Guan & Shenglong Li

4. Institute of Cancer Medicine, Faculty of Medicine, Dalian University of Technology, No.2 Linggong Road, Ganjingzi District, Dalian, 116024, Liaoning Province, China

   Yujing Guan & Shenglong Li

Authors

1. Qiang LiuView author publications

   You can also search for this author in PubMed Google Scholar

2. Yujing GuanView author publications

   You can also search for this author in PubMed Google Scholar

3. Shenglong LiView author publications

   You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shenglong Li.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doi.org/10.1186/s12943-024-02095-8.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

Cite this article

Liu, Q., Guan, Y. & Li, S. Correction: Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the “all-around warrior” in immunotherapy. Mol Cancer 23, 199 (2024). https://doi.org/10.1186/s12943-024-02121-9

Download citation

• Published: 14 September 2024

• DOI: https://doi.org/10.1186/s12943-024-02121-9

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative